PubRank

Yujin Hoshida

Author PubWeight™ 87.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009 6.35
2 SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011 4.57
3 Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008 4.35
4 Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008 4.03
5 Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012 3.67
6 Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008 3.55
7 Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011 2.66
8 Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009 2.42
9 Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013 2.42
10 Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 2014 2.40
11 Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010 2.40
12 Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011 2.39
13 Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 2003 2.06
14 Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 2008 1.99
15 MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011 1.77
16 Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 2012 1.71
17 IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010 1.66
18 UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in japanese patients with hepatitis C virus infection. Clin Cancer Res 2004 1.62
19 Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways. Gastroenterology 2005 1.50
20 New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010 1.46
21 Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012 1.44
22 mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 2011 1.40
23 Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. Oncogene 2005 1.28
24 Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 2012 1.26
25 Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology 2013 1.26
26 Topological and functional discovery in a gene coexpression meta-network of gastric cancer. Cancer Res 2006 1.22
27 Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 2009 1.17
28 Relevance network between chemosensitivity and transcriptome in human hepatoma cells. Mol Cancer Ther 2003 1.12
29 Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology 2011 1.07
30 Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 2005 0.99
31 Expression profiling of archival tumors for long-term health studies. Clin Cancer Res 2012 0.96
32 Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004 0.95
33 Depicting the role of TP53 in hepatocellular carcinoma progression. J Hepatol 2011 0.92
34 Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients. World J Gastroenterol 2005 0.92
35 Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology 2005 0.89
36 Proteomic analysis of the TGF-beta signaling pathway in pancreatic carcinoma cells using stable RNA interference to silence Smad4 expression. Biochem Biophys Res Commun 2004 0.87
37 Prolonged therapy for hepatitis C with low-dose peginterferon. N Engl J Med 2009 0.84
38 Inherited hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2010 0.83
39 Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma. Hepatology 2013 0.83
40 Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence. J Hepatol 2009 0.82
41 Tumor-derived molecular information and outcome in hepatocellular carcinoma. J Hepatol 2009 0.82
42 Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy. Int J Oncol 2004 0.82
43 NF-kappaB and ERK-signaling pathways contribute to the gene expression induced by cag PAI-positive-Helicobacter pylori infection. World J Gastroenterol 2005 0.81
44 Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis. Oncol Rep 2005 0.80
45 Changes in hepatic functional reserve after percutaneous tumor ablation for hepatocellular carcinoma: long-term follow up for 227 consecutive patients with a single lesion. Hepatol Int 2007 0.80
46 Hepatocellular carcinoma enters the sequencing era. Gastroenterology 2011 0.80
47 Hippo tumor supressor pathway: novel implications for the treatment of hepatocellular carcinoma. Gastroenterology 2010 0.79
48 Prognostic gene signatures for hepatocellular carcinoma: what are we measuring? Ann Surg Oncol 2013 0.78
49 A simple combination of serum type IV collagen and prothrombin time to diagnose cirrhosis in patients with chronic active hepatitis C. Hepatol Res 2004 0.78
50 Vitamin K2 binds 17beta-hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism. Life Sci 2005 0.76
51 CXCR4 pathway associated with family history of melanoma. Cancer Causes Control 2013 0.76
52 Reply: To PMID 24677197. Hepatology 2014 0.75
53 [Study of digestive diseases in post-genome era]. Nihon Shokakibyo Gakkai Zasshi 2003 0.75